OBJECTIVE: To develop RNA splicing biomarkers of disease severity and therapeutic response in myotonic dystrophy type 1 (DM1) and type 2 (DM2). METHODS: In a discovery cohort, we used microarrays to perform global analysis of alternative splicing in DM1 and DM2. The newly identified splicing changes were combined with previous data to create a panel of 50 putative splicing defects. In a validation cohort of 50 DM1 subjects, we measured the strength of ankle dorsiflexion (ADF) and then obtained a needle biopsy of tibialis anterior (TA) to analyze splice events in muscle RNA. The specificity of DM-associated splicing defects was assessed in disease controls. The CTG expansion size in muscle tissue was determined by Southern blot. The reversibility of splicing defects was assessed in transgenic mice by using antisense oligonucleotides to reduce levels of toxic RNA. RESULTS: Forty-two splicing defects were confirmed in TA muscle in the validation cohort. Among these, 20 events showed graded changes that correlated with ADF weakness. Five other splice events were strongly affected in DM1 subjects with normal ADF strength. Comparison to disease controls and mouse models indicated that splicing changes were DM-specific, mainly attributable to MBNL1 sequestration, and reversible in mice by targeted knockdown of toxic RNA. Splicing defects and weakness were not correlated with CTG expansion size in muscle tissue. INTERPRETATION: Alternative splicing changes in skeletal muscle may serve as biomarkers of disease severity and therapeutic response in myotonic dystrophy.
OBJECTIVE: To develop RNA splicing biomarkers of disease severity and therapeutic response in myotonic dystrophy type 1 (DM1) and type 2 (DM2). METHODS: In a discovery cohort, we used microarrays to perform global analysis of alternative splicing in DM1 and DM2. The newly identified splicing changes were combined with previous data to create a panel of 50 putative splicing defects. In a validation cohort of 50 DM1 subjects, we measured the strength of ankle dorsiflexion (ADF) and then obtained a needle biopsy of tibialis anterior (TA) to analyze splice events in muscle RNA. The specificity of DM-associated splicing defects was assessed in disease controls. The CTG expansion size in muscle tissue was determined by Southern blot. The reversibility of splicing defects was assessed in transgenic mice by using antisense oligonucleotides to reduce levels of toxic RNA. RESULTS: Forty-two splicing defects were confirmed in TA muscle in the validation cohort. Among these, 20 events showed graded changes that correlated with ADF weakness. Five other splice events were strongly affected in DM1 subjects with normal ADF strength. Comparison to disease controls and mouse models indicated that splicing changes were DM-specific, mainly attributable to MBNL1 sequestration, and reversible in mice by targeted knockdown of toxic RNA. Splicing defects and weakness were not correlated with CTG expansion size in muscle tissue. INTERPRETATION: Alternative splicing changes in skeletal muscle may serve as biomarkers of disease severity and therapeutic response in myotonic dystrophy.
Authors: J M Rojas; M Subleski; J J Coque; C Guerrero; R Saez; B Q Li; E Lopez; N Zarich; P Aroca; T Kamata; E Santos Journal: Oncogene Date: 1999-03-04 Impact factor: 9.867
Authors: Takashi Kimura; Masayuki Nakamori; John D Lueck; Pierre Pouliquin; Futoshi Aoike; Harutoshi Fujimura; Robert T Dirksen; Masanori P Takahashi; Angela F Dulhunty; Saburo Sakoda Journal: Hum Mol Genet Date: 2005-06-22 Impact factor: 6.150
Authors: Xiaoyan Lin; Jill W Miller; Ami Mankodi; Rahul N Kanadia; Yuan Yuan; Richard T Moxley; Maurice S Swanson; Charles A Thornton Journal: Hum Mol Genet Date: 2006-05-22 Impact factor: 6.150
Authors: J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson Journal: Cell Date: 1992-02-21 Impact factor: 41.582
Authors: Paul J Gardina; Tyson A Clark; Brian Shimada; Michelle K Staples; Qing Yang; James Veitch; Anthony Schweitzer; Tarif Awad; Charles Sugnet; Suzanne Dee; Christopher Davies; Alan Williams; Yaron Turpaz Journal: BMC Genomics Date: 2006-12-27 Impact factor: 3.969
Authors: Alexander Manta; Derek W Stouth; Donald Xhuti; Leon Chi; Irena A Rebalka; Jayne M Kalmar; Thomas J Hawke; Vladimir Ljubicic Journal: J Physiol Date: 2019-01-30 Impact factor: 5.182
Authors: Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits Journal: Proc Natl Acad Sci U S A Date: 2013-10-29 Impact factor: 11.205
Authors: Ranjan Batra; David A Nelles; Elaine Pirie; Steven M Blue; Ryan J Marina; Harrison Wang; Isaac A Chaim; James D Thomas; Nigel Zhang; Vu Nguyen; Stefan Aigner; Sebastian Markmiller; Guangbin Xia; Kevin D Corbett; Maurice S Swanson; Gene W Yeo Journal: Cell Date: 2017-08-10 Impact factor: 41.582
Authors: Samuel T Carrell; Ellie M Carrell; David Auerbach; Sanjay K Pandey; C Frank Bennett; Robert T Dirksen; Charles A Thornton Journal: Hum Mol Genet Date: 2016-08-13 Impact factor: 6.150
Authors: Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan Journal: Hum Mol Genet Date: 2020-06-03 Impact factor: 6.150